Form 4: DENTSPLY SIRONA CEO Reports Future Tax-Related Stock Withholding Under 10b5-1 Plan

DENTSPLY SIRONA Inc. CEO Simon D. Campion reported a future disposition of 32,566 shares of common stock on July 28, 2025, for tax withholding purposes related to Restricted Stock Unit vesting, executed under a Rule 10b5-1 plan.

Summary

• Simon D. Campion, President and CEO of DENTSPLY SIRONA Inc. (XRAY), filed a Form 4 reporting a change in beneficial ownership.
• The transaction involves the disposition of 32,566 shares of Common Stock at a price of $16.07 per share.
• The transaction date is listed as July 28, 2025, which is a future date relative to the filing date of July 30, 2025.
• The disposition is coded as 'F', indicating shares withheld to cover taxes related to the vesting of the reporting person's Restricted Stock Units (RSUs) and dividend equivalent units.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this reported transaction, Simon D. Campion will beneficially own 239,837.9801 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary tax-related disposition of shares by the CEO, which is a neutral event. The use of a 10b5-1 plan for a future transaction is a standard practice.

Positives

• The transaction is a routine tax withholding event associated with the vesting of Restricted Stock Units, indicating the executive's compensation structure is functioning as expected.
• The transaction is pre-planned and executed under a Rule 10b5-1 plan, which demonstrates a structured approach to managing equity compensation and reduces concerns about discretionary insider selling.

Negatives

• The disposition of shares, even for tax purposes, reduces the direct ownership stake of the CEO, though this is a common occurrence with RSU vesting.

Risks

• There is a potential for misinterpretation by investors due to the future transaction date (July 28, 2025) being reported on a current filing (July 30, 2025), although this is clarified by the 10b5-1 plan disclosure.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is solely focused on an insider's equity transaction.

Management Comments

• Shares were withheld to cover taxes related to the vesting of the reporting person's Restricted Stock Units and dividend equivalent units previously reported in Table I.

Industry Context

This Form 4 filing is specific to an insider transaction at DENTSPLY SIRONA Inc. and does not provide broader insights into industry trends or competitive dynamics within the dental products and technologies sector. Such tax-related dispositions are common across all industries for executives receiving equity compensation.

Comparison to Industry Standards

• The practice of withholding shares to cover tax obligations upon the vesting of Restricted Stock Units is a standard and common method of managing equity compensation for executives across publicly traded companies, including those in the healthcare and medical device industries.
• The use of a Rule 10b5-1 plan for such transactions is also a widely adopted corporate governance practice, providing a pre-arranged schedule for stock sales or dispositions to avoid accusations of insider trading.

Stakeholder Impact

• Shareholders: The disposition is a routine tax event and does not reflect a discretionary sale by the CEO, thus having minimal direct impact on shareholder sentiment or company valuation.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• No specific future actions or milestones are mentioned in this filing beyond the scheduled transaction date.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary tax-related disposition of shares by the CEO under a pre-arranged 10b5-1 plan. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is an expected part of executive compensation and does not signal any fundamental shift in the company's outlook.

Keywords

DENTSPLY SIRONA, XRAY, Form 4, Insider Transaction, CEO, Simon D. Campion, Restricted Stock Units, RSU Vesting, Tax Withholding, 10b5-1 Plan, Equity Compensation